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Variable response to bronchodilator therapy 
children born prematurely 
B. YUKSELAND A. GREENOUCH* 
Department of Child Health, King’s College Hospital, London SE5 9RS, U.K. 
The response to nebulized therapy was studied at a median postnatal age of 16 months (range 624 months) in 15 
children born prematurely. Thoracic gas volume (TGV) and airways resistance (RAW) were measured by total 
body plethysmography and specific conductance (SGAW) calculated. The measurements were made prior to, and 
then 5 and 10 min after, nebulized saline (3 ml), and then 5, 10 and 15 min after administration of nebulized 
salbutamol (2.5 mg in 2.5 ml normal saline). There was no significant change in TGV throughout the study 
period. One child showed a significant improvement in airways resistance following nebulized saline, and no 
child had a significant deterioration. RAW and SGAW both significantly improved in the group overall at 15 min 
following salbutamol (P < 0.05, P < 0.03 respectively). Individual patients, however, showed a variable serial 
response in RAW and SGAW: four children had a paradoxical response (an increase in RAW and a decrease in 
SGAW) at 5 min and at 10 or 15 min, seven children had a significant improvement (decrease) in RAW and eight a 
significant improvement (decrease) in SGAW. The children who had an initial paradoxical effect did not differ 
significantly in either age or baseline lung function from the other infants. Patients in whom RAW and SGAW 
improved following bronchodilator did not differ in age from the rest of the study group, but had tended to have 
worse lung function prior to bronchodilator administration. We conclude that there is a variable response to 
nebulized salbutamol in children born preterm, this treatment should only be administered in association with 
careful monitoring. 
Introduction 
Maintenance therapy with inhaled salbutamol 
reduces symptoms in wheezy preterm infants seen at 
follow-up (1). Nebulized salbutamol has an immediate 
benefit in preterm infants less than 1 year of age, 
acutely improving lung function, assessed by plethys- 
mographic measurements (2). This positive response 
to bronchodilator therapy was usually related to the 
presence of symptoms, being less common amongst 
asymptomatic infants. In contrast, in infants born 
at term, nebulized bronchodilator not only fails to 
acutely improve lung function, but may even cause a 
paradoxical response, with a deterioration in airways 
resistance (3). This paradoxical response might be 
caused by the acidity or osmolality of the solution 
(3), but we had apparently used a similar nebulized 
solution and failed to detect such a deterioration in 
preterm infants (2). Thus, it is possible that infants 
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born preterm rather than at term may respond differ- 
ently to nebulized therapy. A further explanation for 
differences in the results (2,3) is that we (2) had only 
measured airways resistance 10 min after adminis- 
tration of bronchodilator therapy, as had Prendiville 
et al. (4) who also failed to document a paradoxical 
deterioration in airways resistance even in term 
infants. O’Callaghan et al. (3) however, had made 
serial measurements and found that the paradoxical 
bronchoconstriction, although lasting up to 15 min, 
was greatest at 5 min. It is possible therefore, that by 
studying preterm infants only at 10 min we had missed 
the paradoxical response. Nebulized salbutamol in 
certain preterm infants might uniquely result firstly in 
a deterioration in lung function, rapidly followed by 
an improvement. The aim of this study was to test 
this hypothesis by performing serial measurements of 
airway resistance (RAW) and specific conductance 
(SGAW) following administration of nebulized salbuta- 
mol and saline in both asymptomatic and symptomatic 
children born preterm. We also hoped to determine 
factors influencing the acute response to nebulized 
treatments. 
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Table I Patients’ characteristics 
Patient 
Gestational 0, Postnatal 
Birthweight age Ventilation requirement age Weight Height 
(g) (weeks) @I (4 (months) (kg) (cm) Symptomatic 
1 1500 31 48 3 6 644 60.5 - 
2 1100 35 0 0.12 7 6.60 71.0 + 
3 1266 31 48 4 8 6.58 62.6 - 
4 1680 34 0 0 10 8.70 74.7 - 
5 1346 28 2 0.04 12 8.78 72.0 - 
6 844 26 36 3 14 8.60 72.0 + 
7 996 29 204 12 15 8.58 71.0 + 
8 1018 28 144 14 16 10.03 74.5 - 
9 720 21 22 2.5 18 7.88 76.0 
10 1440 28 2 0.67 19 10.00 81.0 r 
11 562 21 6 15 20 7.14 72.7 - 
12 1358 30 192 14 24 11.66 87.5 - 
13 1440 34 3 0.75 24 11.05 86.0 - 
14 1086 29 192 26 24 11.00 85.8 - 
15 816 25 48 4 24 12.41 82.0 + 
Patients 
Fifteen young children, all born prematurely, were 
enrolled into the study, eight boys and seven girls with 
a median birthweight of 1266 g (range 562-1700) and 
gestational age 29 weeks (25-35). They were studied 
at a median postnatal age of 16 months (range 624 
months). All but one child had suffered from the 
respiratory distress syndrome (RDS), one patient had 
required an increase in the inspired oxygen (0,) 
concentration only and the remaining 13 had been 
ventilated (Table 1). Four patients had recurrent 
respiratory symptoms: they coughed and/or wheezed 
on at least 3 days per week for the previous 4 weeks, the 
remaining 11 were asymptomatic. 
This study was approved by the King’s College 
Hospital’s Ethics Committee. 
Methods 
The children were seen in the Paediatric Respiratory 
Laboratory where height and weight were recorded 
and the patients examined. Sedation was achieved with 
oral chloral hydrate (100mg kg-‘). Thoracic gas 
volume (TGV) and airway resistance (RAW) were 
measured during quiet sleep, in a whole body plethys- 
mograph. Specific conductance (SGAW) was calcu- 
lated from TGV and RAW. Measurements were made 
before, then 5 and 10 min after nebulized normal saline 
(3 ml), then 5, 10min after nebulized salbutamol 
(2.5 mg in 3 ml of normal saline). In children who 
remained asleep, measurements following salbutamol 
were also made at 15 min. We only studied the children 
up to 10 min following nebulized normal saline as we 
(2) had not previously documented this treatment to 
cause any significant improvement in lung function, 
and we were particularly interested to assess if 
nebulized saline might cause a paradoxical deterio- 
ration in lung function at 5 min. The solutions were 
administered in random order via a mini-Neb nebulizer 
(Bard Ltd) using an inspiron compressor with a flow of 
8 1 min-’ for 4 min. The nebulizer has a 20 ml capacity 
and 80% of the particles produced are in the range 
l-3 ,um. 
LUNG FUNCTION MEASUREMENTS 
During the measurements the children breathed 
through a face mask which was connected to the 
rebreathing bag via a heated pneumotachograph, and 
sealed around the nose and mouth with silicone putty 
to ensure an airtight seal. The child breathed through a 
heated, humidified rebreathing system to avoid box 
pressure changes due to the heating and cooling of 
respired gas. The servo-controlled heating system 
maintained the face mask and humidified rebreathing 
bag at 36°C. TGV was measured at the end of inspi- 
ration and RAW at two-thirds of inspiratory flow as 
previously described by Radford (5) and Dubois et al. 
(6,7). TGV was calculated from five breaths during 
occlusion, and at least five occlusions were made. RAW 
was calculated from a minimum of 10 breaths when 
flow and pressure signals were in phase. Flow, volume, 
box and mask pressure changes were simultaneously 
recorded on ultraviolet recording paper. All plethys- 
mographic traces were analysed blind ofclinical details 
by one observer. The measurements were corrected for 
Bronchodilator therapy in preterm infants 361 
apparatus dead space (15 ml) and resistance (8 cmH,O 
I-’ ss’ measured at flows between 5-20 1 min-‘). 
The reproducibility of TGV and RAW measure- 
ments were assessed by repeated measurements in 16 
patients of similar gestational age and postnatal age to 
the study population. The coefficient of variation of 
TGV and RAW was calculated from at least five 
measurements before and after infants had been 
removed and returned to the body plethysmograph. 
The maximum coefficient of variation of the 16 
patients was 8% for TGV and 10% for RAW, hence a 
statistically significant change in RAW was defined 
as greater than 20%. SGAW was calculated from the 
results of TGV and RAW and the maximum coefficient 
of variation was determined to be lo%, hence a statis- 
tically significant change in SGAW was defined as 
greater than 20%. 
STATISTICAL ANALYSIS 
Differences were assessed for statistical significance 
using a paired or non-paired Wilcoxon Rank Sum test, 
as appropriate, and Fisher’s exact test. 
Results 
There was no significant change in TGV following 
either nebulized therapy throughout the study period 
(Tables 2, 3). RAW and SGAW both significantly 
improved at 15 min following nebulized salbutamol 
compared to baseline (PC 0.05, P-co.03 respectively). 
At 5 min after nebulized saline there was no signifi- 
cant deterioration in either RAW or SGAW (Table 2). 
Following nebulized salbutamol at 5 min RAW and 
SGAW deteriorated significantly in four patients 
(paradoxical response). 
At 10 min following administration of nebulized 
saline there was a significant change in lung function in 
only one patient. This was a decrease in RAW and an 
increase in SGAW. Following nebulized salbutamol 
there was a significant increase in RAW and a decrease 
in SGAW in one child (paradoxical response), a 
decrease in RAW in three children and an increase 
in SGAW in four children (positive bronchodilator 
response). At 15 min following nebulized salbutamol, 
one patient had an increase in RAW and a decrease in 
SGAW (paradoxical response), seven had a decrease in 
RAW and eight had an increase in SGAW (a positive 
bronchodilator response). 
There was no significant difference in the postnatal 
age or baseline airways resistance of the children who 
showed a significant deterioration in RAW and SGAW 
at 5 min following bronchodilator (median age 19 
months, range 8-24; median RAW 30.5 cmH,O I-’ s-‘, 
range 21-63; median SGAW 0.121 s-’ cmH,O-‘, range 
0.093+192), compared to those who did not (median 
16months, range 6-24; median RAW 30cmH,O ll’ SK’, 
range 2461, median SGAW 0.102 ss’ cmH,O-‘, range 
0.083-0.161). There was no significant difference in the 
postnatal age of those children who showed a reduction 
in RAW at 10 or 15 min (median age 18 months, range 
6-24) compared to those who did not (median age 13 
months, range 7-24); but the airways resistance tended 
to be higher in those patients in whom RAW improved 
following bronchodilator (median RAW 34 cmH,O ll’ 
SK’, range 2161 compared to median RAW 29 cmH,O 
1-l s-‘, range 2463). Specific conductance was 
higher in the children who had a positive response to 
bronchodilator (median 0.110 SK’ cmH,O-‘, range 
0,083X). 192) compared to those who did not (median 
0.093 ss’ cmH,O-‘, range 0.085+161). 
One patient only with a significant paradoxical 
response to salbutamol at 5 min had a significant 
improvement in RAW and SGAW at 15 min, this child 
had recurrent symptoms. 
Discussion 
Nebulized salbutamol resulted in a change in 
airways resistance in the majority of patients studied, 
although the response seen was variable and in one 
patient both a significant deterioration and then an 
improvement in lung function was documented. We 
feel that this does reflect a response to the nebulized 
salbutamol, for although changes in lung function 
were seen in response to nebulized saline these were 
usually small and were only significant in one child. 
This change in lung function in response to salbutamol 
suggests that there are functional &adrenergic 
receptors in the airways of preterm children even as 
young as 6 months of age. This hypothesis is supported 
by data from children born at term, studied between 
3 and 15 months, in whom nebulized salbutamol 
resulted in a decline in maximum flow at functional 
residual capacity (4). 
In certain of our patients nebulized salbutamol 
resulted in an improvement in lung function. This 
effect was not related to the infant’s age. Certain of 
the patients we studied had lung function within the 
normal range for similarly-aged patients born at term 
(8). It is of interest that the improvement in lung func- 
tion in response to the bronchodilator tended to occur 
in the infants with the worst lung function, as indicated 
by an elevated airways resistance. We (2) had pre- 
viously found a positive response to bronchodilator 
was more common in preterm infants, symptomatic 
at follow-up. The infants also had more severe lung 
function abnormalities. 
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We also documented in certain children a significant 
paradoxical response to nebulized salbutamol, but 
only in one child to nebulized saline. We administered 
the solutions in random order, thus it is possible that 
in certain patients salbutamol administered first may 
have blocked a bronchoconstrictor response to saline. 
In our previous study, however, we found that nebu- 
lized saline did not cause a significant change in lung 
mechanics (2). Unlike O’Callaghan et al. (3), we found 
this response rarely persisted to 10 min after adminis- 
tration of the medication. The exact duration of 
the paradoxical response might, however, have been 
masked in certain patients who subsequently showed a 
positive response to the bronchodilator. 
children in whom nebulized salbutamol will improve 
lung function, but also those in whom its use should be 
avoided. 
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